E
4.76
0.01 (0.21%)
| Previous Close | 4.75 |
| Open | 4.75 |
| Volume | 5,044 |
| Avg. Volume (3M) | 174,439 |
| Market Cap | 7,418,294 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| Profit Margin | -43.80% |
| Operating Margin (TTM) | -42.26% |
| Diluted EPS (TTM) | -1.23 |
| Quarterly Revenue Growth (YOY) | 77.50% |
| Total Debt/Equity (MRQ) | 88.08% |
| Current Ratio (MRQ) | 1.55 |
| Operating Cash Flow (TTM) | -3.88 M |
| Levered Free Cash Flow (TTM) | -2.26 M |
| Return on Assets (TTM) | -21.70% |
| Return on Equity (TTM) | -108.77% |
AIStockmoo Score
| Value 38% | -2.2 |
| Weak profitability. Negative cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Return on Capital info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 38% | 3.4 |
| Uptrend over the past year. Trading near its 52-week high. info | |
| Near its medium-term trend line. info | |
| From our AI technical analysis of the chart. info | NA |
| Technical Setup info | NA |
| Candle Patterns info | NA |
| Sentiment 25% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| Holdings' Sentiment info | NA |
| News Mood info | NA |
| Smart Money | NA |
| Insider Activity info | NA |
| Institutional Flow info | NA |
| Short Interest info | NA |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector outperforming the market. | |
| The pillars disagree, so the score is softened. | |
| Not in score | |
| Earnings per share have risen every year. Made a loss in recent years. info | |
| Price is near its 52-week average. Down over 5 years. info | |
| No clear trend across the short, medium and long term. info | |
| Price is near support. info | |
| Final Score | 0.37 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Evoke Pharma, Inc. | - | - |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| EVOK | 7 M | - | - | - | 0.4 |
| SUPN | 6 B | 27.84% | - | 1.59 | -1.0 |
| ANIP | 2 B | - | 13.74 | 2.57 | -0.1 |
| COLL | 783 M | - | 23.13 | 2.72 | 0.1 |
| TKNO | 480 M | - | - | - | 0.8 |
| AQST | 435 M | - | - | - | -1.7 |
Select this tab to load the latest available analysis.
|
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 1.34% |
| % Held by Institutions | 16.23% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |